Psilocybin
Algernon Pharmaceuticals completes final dosing in DMT study for stroke and TBI treatment
AGN Neuro plans to publish the data from the study in an upcoming issue of a peer-reviewed paper
The post Algernon Pharmaceuticals completes final dosing…
Algernon Pharmaceuticals Inc.’s (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) subsidiary Algernon Neuroscience will be the first company to test intravenous (IV) DMT on people suffering from traumatic brain injury or stroke.
On Monday, the clinical-stage pharmaceutical development company announced the successful completion of dosing in the final cohort of its Phase 1 clinical study involving AP-188 which is DMT.
AGN Neuro is the first company to test DMT at single escalating concentrations with an IV dose for a 6-hour duration. The safety review committee has confirmed no safety or tolerability issues with the highest dose.
This dose maintained plasma DMT concentrations at targeted levels and was below the established psychedelic dose.
The psychedelic dose of DMT was previously identified as 0.2 mg/kg by Dr. Rick Strassman, a DMT researcher and Algernon consultant, in his pioneering DMT human studies in the early 1990s.
DMT is believed to activate pathways involved in forming neuronal connections and has been shown to increase the number of dendritic spines on cortical neurons. These spines form synapses with other neurons and are a critical site for neuronal transmission.
The Phase 1 trial was conducted at the Centre for Human Drug Research in Leiden, Netherlands. It aimed to identify the safety, tolerability and pharmacokinetics of sub-psychedelic doses of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours.
AGN Neuro plans to publish the data from the study in an upcoming issue of a peer-reviewed paper.
“Neuroplasticity’s role in healing the brain after an injury is one of the most exciting areas of research globally in the pursuit of a treatment for stroke and TBI, and AGN Neuro is at the forefront of this work,” Algernon CEO Christopher J. Moreau said.
Read more: Algernon partners with Yale University for phase II DMT study
Read more: Small Pharma gets approval for upcoming injectable DMT trial on humans
DMT assists in brain recovery post-injury
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.
DMT occurs naturally in many plant species and animals, including humans, and has been used in religious ceremonies as a traditional spiritual medicine by Indigenous people in the Amazon basin.
The molecule acts on various receptors, such as serotonin receptors and the multi-functional sigma-1 receptor. The sigma-1 receptor responds to stress and supports cell survival, neuroprotection, neuroplasticity and neuroimmunomodulation. Additionally, DMT stimulates the release of Brain-Derived Neurotrophic Factor (BDNF), a protein that assists in brain recovery post-injury.
Algernon has submitted patent applications for DMT pamoate and nicotinate, which are innovative salt forms of DMT. These applications extend to the formulation, dosage and usage for ischemic stroke and TBI. The company has also proposed patents for a combined therapy approach involving DMT and stroke rehabilitation, specifically Constraint Induced Movement Therapy.
Algernon announced last October it entered into a clinical trials agreement with Yale University to supply cGMP DMT to a study looking into DMT as a treatment for depression.
The post Algernon Pharmaceuticals completes final dosing in DMT study for stroke and TBI treatment appeared first on Mugglehead Magazine.
psilocybin lsd ketamine dmt n-dimethyltryptamine dimethyltryptamine psychedelic therapy depression serotonin hallucinogenic psychedelics cse algernon pharmaceuticals algernon small pharma research-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment